New updates have been reported about Neurent Medical.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurent Medical has raised an oversubscribed €62.5 million ($74 million) Series C round to accelerate commercialization of its NEUROMARK system for chronic rhinitis and to fund pipeline development. The financing, led by MVM Partners with major participation from Sofinnova Partners and continued backing from EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland, signals growing investor conviction in the company’s market opportunity and technology.
The new capital will support U.S. and international commercial expansion, additional clinical studies to strengthen evidence across broader patient populations, and advancement of new indications built on Neurent’s Impedance Controlled Radiofrequency platform. NEUROMARK targets overactive posterior nasal nerves to deliver minimally invasive, durable symptom relief for chronic rhinitis, positioning Neurent to shape a new standard of care in an underserved, high-prevalence condition.
As part of the transaction, MVM Partner Kyle Dempsey and Sofinnova Partner Cedric Moreau join Neurent Medical’s Board of Directors, bolstering strategic and sector expertise at a pivotal commercialization stage. Both investors highlighted the scale of unmet need in chronic rhinitis, the differentiated, feedback-driven nature of NEUROMARK’s technology, and the platform’s potential to extend into additional ENT indications.
CEO Brian Shields emphasized that the funding will be deployed to expand patient and physician access, deepen clinical validation, and progress the company’s broader portfolio of minimally invasive ENT solutions. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Mass., Neurent Medical is positioning NEUROMARK as a best-in-class option in the rapidly emerging posterior nasal nerve ablation category.
For executives and stakeholders, this Series C materially extends Neurent’s runway, strengthens its balance sheet ahead of broader commercial rollout, and aligns the company with experienced growth-stage medtech investors. The move underscores a strategic push to convert strong clinical data and early adoption into scaled market penetration in chronic inflammatory sinonasal disease management.